HCC Clinical Trial
— YH001Official title:
An Open-Label, Non-Randomized, Multi-center Phase 2 Study of YH001 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC) and Hepatocellular Carcinoma (HCC)
NCT number | NCT05212922 |
Other study ID # | YH001004 |
Secondary ID | |
Status | Withdrawn |
Phase | Phase 2 |
First received | |
Last updated | |
Start date | June 2023 |
Est. completion date | March 2025 |
Verified date | November 2022 |
Source | Eucure (Beijing) Biopharma Co., Ltd |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is an Open-label, Non-Randomized, Multi-center Phase 2 study of YH001 in Combination with Toripalimab,The study is designed to determine the safety ,tolerability and antitumor activity of YH001 in combination with Toripalimab in subjects with advanced NSCLC and HCC.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | March 2025 |
Est. primary completion date | December 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Male or female, aged = 18 years; 2. Willing and able to provide signed and dated informed consent prior to any study-related procedures and willing and able to comply with all study procedures. 3. Target Population Cohort A: - Have histologically or cytologically confirmed diagnosis of NSCLC (squamous or non-squamous) - Recurrent or unresectable locally advanced (Stage IIIB) or metastatic (Stage IV); - Naïve to any systemic anti-cancer therapy - No EGFR mutation or ALK/ ROS1 gene rearrangement - PD-L1 positive (TPS=1%) NSCLC Cohort B: - HCC diagnosis confirmed by or radiology, histology, or cytology; - Barcelona Clinic Liver Cancer (BCLC) Stage C or BCLC Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy and not amenable to a curative treatment approach; - Child-Pugh A liver score within 7 days prior to first dose of study drug; - Documented objective radiographic progression during or after treatment with sorafenib/lenvatinib, or intolerant of sorafenib/lenvatinib; or documented objective radiographic progression during or after treatment with atezolizumab and bevacizumab, or intolerant of atezolizumab and bevacizumab. 4. At least 1 unidimensional measurable target lesion per RECIST v1.1 5. ECOG performance status score 0 or 1 6. Have life expectancy of at least 12 weeks based on investigator's judgement. 7. Adequate organ and bone marrow function: 8. Women of reproductive potential must have negative serum beta human chorionic gonadotropin (ß -HCG) pregnancy test within 7 days of the fist dose of YH001. 9. Women of reproductive potential who are sexually active with a non-sterilized male must consistently use highly effective contraception/birth control between signing of the informed consent and 120 days after the last administration of the study drug. Exclusion Criteria: 1. Treatment with any investigational drug within 4 weeks prior to the fist dose of study drug; 2. Prior anticancer therapy: - Cohort B: Subjects received sorafenib/lenvatinib within 14 days of first dose of study medication. - Prior palliative radiotherapy to bone metastases = 2 weeks prior to the first dose of YH001 is acceptable. - It is unacceptable to have wash out less than 2 weeks for herbal therapy approved for anticancer. 3. Subjects with prior anti-CTLA-4 checkpoint inhibitors should be excluded. 4. Subjects with a history of = Grade 3 immune-related adverse events resulted from previous immunotherapy or an AE of any grade that resulted in discontinuation of prior immunotherapy 5. History of (non-infectious) pneumonitis that required corticosteroids or current pneumonitis, or history of interstitial lung disease 6. Subjects requiring systemic treatment with corticosteroids (>10 mg/day prednisone or equivalent) or other immunosuppressive medications within 21 days before the planned first dose of study drug or has need to be treated while on trial 7. Allergic to YH001 and Toripalimab or any component of the study drug formulation. 8. Subjects with concomitant active autoimmune disease, history of autoimmune disease requiring systemic treatment, or history of autoimmune disease within the two years prior to study entry. 9. Primary central nervous system (CNS) malignancies or symptomatic CNS metastases. 10. Subjects with severe cardiovascular diseases, e.g. New York Heart Association (NYHA) Class III or IV heart failure, myocardial infection within 6 months prior to first dose of YH001, uncontrolled hypertension, unstable angina pectoris or unstable cardiac arrhythmia. 11. QTcF > 470 ms at baseline; no concomitant medications that would prolong the QT interval; no family history of long QT syndrome. 12. Viral infection: - Acute or Chronic active Hepatitis B (HBsAg positive and HBV DNA=2000 IU/mL). - Chronic HCV infection (HCV antibody positive and HCV RNA detectable). - Human immunodeficiency virus (HIV) infection as well as COVID-19. 13. Subjects with active tuberculosis are excluded. Subjects who have received BCG vaccination may have a false positive PPD test. These subjects are eligible if they have a negative Interferon Gamma Release Assay (IGRA). 14. Clinically uncontrolled concurrent illnesses, including, but not limited to, active infection that requires systematic treatment, serious diabetes (fasting blood glucose > 250 mg/dl), psychiatric illness that would limit compliance with the study requirements and other serious medical illnesses requiring systemic therapies. 15. Continuance of toxicities due to prior radiotherapy or chemotherapy agents that have not recovered to = Grade 1 per CTCAE v5.0 16. Failure to recover adequately, as judged by the investigator, from prior surgical procedures; the subjects have had major surgery within 28 days, or minor surgery within 2 weeks prior to the first dose of YH001. 17. Subjects received any live or attenuated vaccine within 28 days prior to the first dosing of study drug. For inactivated or attenuated COVID -19 vaccine, follow local guidelines. 18. Pregnant or breast-feeding females. 19. Any clinically significant abnormality in the laboratory 20. Subjects have another active invasive malignancy within 5 years 21. Cohort B: - History of esophageal or gastric variceal bleeding within the last 6 months, or current active gastrointestinal bleeding; - Large tumor lesion in liver (=60% liver volum), portal vein invasion at the main portal branch (Vp4), inferior vena cava, or cardiac involvement of HCC based on imaging; - Clinically diagnosed hepatic encephalopathy in the last 6 months |
Country | Name | City | State |
---|---|---|---|
Armenia | Gabrail Cancer Center Research | Canton | Ohio |
Australia | Andrew Love Cancer Centre | Geelong | Victoria |
Australia | University of New South Wales (UNSW) - Liverpool Hospital | Liverpool | New South Wales |
Austria | Coffs Harbour Health Campus | Coffs Harbour | New South Wales |
China | Beijing Cancer Hospital | Beijing | Beijing |
China | Beijing Tsinghua Changgung Hospital | Beijing | Beijing |
China | Bethune First Hospital Of Jilin University | Changchun | Jilin |
China | West China Hospital of Sichuan University | Chengdu | Sichuan |
China | Sir Run Run Shaw Hospital Zhejiang University School Of Medicine | Hangzhou | Zhejiang |
China | The Affiliated Tumour Hospital of Harbin Medical University | Harbin | Heilongjiang |
China | Nantong Tumor Hospital | Nantong | Jiangsu |
China | Shanghai Pulmonary Hospital | Shanghai | Shanghai |
China | Hubei Cancer Hospital | Wuhan | Hubei |
China | Zhongnan Hospital of Wuhan University | Wuhan | Hubei |
China | Henan Cancer Hospital | Zhengzhou | Henan |
Taiwan | Chang Gung Medical Foundation - Kaohsiung Chang Gung Memorial Hospital | Kaohsiung | |
Taiwan | Kaohsiung Medical University - Chung-Ho Memorial Hospital | Kaohsiung | |
Taiwan | China Medical University Hospital | Taichung | |
Taiwan | Chi Mei Medical Center - Liouying | Tainan | |
Taiwan | Chi Mei Medical Center - YongKang | Tainan | |
Taiwan | Taipei Medical University Hospital | Taipei | |
Taiwan | Taipei Veterans General Hospital | Taipei |
Lead Sponsor | Collaborator |
---|---|
Eucure (Beijing) Biopharma Co., Ltd |
Armenia, Australia, Austria, China, Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | trough concentration (Ctrough) | To characterize the pharmacokinetic (PK) profiles of YH001 in combination with Toripalimab | maximum of 1 years after the first dose of YH001 and Toripalimab study treatment. | |
Other | terminal half-life (T1/2). | To characterize the pharmacokinetic (PK) profiles of YH001 in combination with Toripalimab | maximum of 1 years after the first dose of YH001 and Toripalimab study treatment. | |
Other | Duration of response (DOR) | To assess other antitumor activity of YH001 in combination with Toripalimab by investigator's assessment according to the RECIST v1.1 | maximum of 1 years after the first dose of YH001 and Toripalimab study treatment. | |
Other | progression free survival (PFS) | To assess other antitumor activity of YH001 in combination with Toripalimab by investigator's assessment according to the RECIST v1.1 | maximum of 1 years after the first dose of YH001 and Toripalimab study treatment. | |
Other | time to response (TTR) | To assess other antitumor activity of YH001 in combination with Toripalimab by investigator's assessment according to the RECIST v1.1 | maximum of 1 years after the first dose of YH001 and Toripalimab study treatment. | |
Primary | ORR | Overall Response Rate (ORR) by investigator's assessment according to the RECIST v1.1 | maximum of 1 years after the first dose of YH001 and Toripalimab study treatment. | |
Secondary | safety and tolerability | The safety and tolerability will be assessed by monitoring the adverse events (AE) per NCI CTCAE v5.0 | maximum of 1 years after the first dose of YH001 and Toripalimab study treatment. | |
Secondary | OS | To assess other antitumor activity of YH001 in combination with Toripalimab | maximum of 1 years after the first dose of YH001 and Toripalimab study treatment. | |
Secondary | anti-drug antibodies (ADA) | Immunogenicity | maximum of 1 years after the first dose of YH001 and Toripalimab study treatment. | |
Secondary | neutralizing antibodies (NAbs). | To assess the immunogenicity of YH001 in combination with Toripalimab | maximum of 1 years after the first dose of YH001 and Toripalimab study treatment. | |
Secondary | peak concentration (Cmax) | To characterize the pharmacokinetic (PK) profiles of YH001 in combination with Toripalimab | maximum of 1 years after the first dose of YH001 and Toripalimab study treatment. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05458115 -
Clinical Study of MRD Recurrence Monitoring After Surgical Resection of Hepatocellular Carcinoma
|
||
Not yet recruiting |
NCT05022628 -
Clinical Study of Radiotherapy Combined With Donafenib for Neoadjuvant Treatment of Patients With HCC With Portal Vein Carcinoma Thrombosis
|
Phase 4 | |
Enrolling by invitation |
NCT02256514 -
Open Label Trial of Immunotherapy for Advanced Liver Cancer
|
Phase 2 | |
Not yet recruiting |
NCT06434480 -
SBRT in HCC With Oligoprogression on Atezo-Bev
|
N/A | |
Completed |
NCT04542837 -
The Study of KN046 in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma
|
Phase 2 | |
Not yet recruiting |
NCT05025592 -
cTACE or DEB-TACE+HAIC Combined With Regorafenib ± Anti-PD1 Antibody for uHCC
|
||
Completed |
NCT04172506 -
A Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05840133 -
Study of Long Non-coding RNA SNHG15 as a Novel Biomarker in HBV Associated HCC
|
||
Not yet recruiting |
NCT06024252 -
Efficacy, Safety, and Treatment Patterns of Transcatheter Arterial Chemoembolization (TACE) Combined With Atezolizumab and Bevacizumab in Unresectable Hepatocellular Carcinoma: a Multicenter, Retrospective, Observational Real-world Study
|
||
Terminated |
NCT02785874 -
Statin With Palliative Therapy for HCC
|
N/A | |
Not yet recruiting |
NCT02715492 -
Role of (LMWH) in Prevention of Thromboembolic Complication After (TACE) in Hepatocellular Carcinoma.
|
Phase 3 | |
Completed |
NCT02985034 -
Safety Margin Assessment After RFA Using the Registration of Pre-ablation MRI and Post-ablation CT
|
N/A | |
Not yet recruiting |
NCT06069947 -
SALT for Liver Cirrhosis With HCC
|
N/A | |
Recruiting |
NCT05581004 -
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
Suspended |
NCT02935478 -
Bariatric Embolization of Arteries in Obese Patients With HCC to Allow Salvage Liver Transplantation
|
N/A | |
Recruiting |
NCT05592171 -
Occlusafe® Assisted MW Alone or With DEB-TACE Compared to MW With DEB-TACE in the Treatment of HCC
|
N/A | |
Completed |
NCT03176485 -
Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors
|
N/A | |
Recruiting |
NCT05544253 -
Safety and Efficacy of Mitomycin C-based HIPEC After srHCC and PM of HCC
|
Phase 2/Phase 3 | |
Recruiting |
NCT06184152 -
CEUS vs. AMRI for HCC Detection in Patients With Indeterminate Liver Nodules
|
||
Completed |
NCT02675920 -
A Study of HCC High Risk Group Using Two Surveillance Tools
|